Braveheart Bio, a cardiac drug developer, successfully priced its initial public offering at $18 per share, raising $382.5 million and exceeding expectations. The company, which aims to compete with Bristol Myers Squibb’s Camzyos for treating hypertrophic cardiomyopathy, licensed its leading drug candidate BHB-1893 from China’s Hengrui Pharma. Founded just a year ago, Braveheart is one of several biotech firms going public in 2026, contributing to a notable trend of biotech IPOs raising substantial funds this year. Alongside Braveheart, Attovia Therapeutics also went public, reflecting a growing demand for shares in the sector.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biopharmadive.com/news/braveheart-cardiac-drugs-ipo-pricing/826973/
